Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 251-257

  Raphael, J ^a   Le Teuff, G ^b   Hollebecque, A ^c   Massard, C ^a,c   Bahleda, R ^c   Margery, J ^c,d   Besse, B ^a,c   Soria, J C ^a,c   Planchard, D ^a,c  

^a Universite Paris Sud   (France)

^b Department of Biostatistics and Epidemiology Gustave Roussy ^*  (France)

^c Drug Development Department   (France)

^d Military Hospital Percy   (France)

Author keywords

Malignant pleural mesothelioma; Molecular pathways; Phase 1; Response rate; Targeted therapy; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; DACARBAZINE; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN KINASE B INHIBITOR; ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ARTICLE; BIOLOGICAL THERAPY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL MOTILITY; CLINICAL ARTICLE; COUGHING; DISEASE ACTIVITY; DISEASE COURSE; DRUG MECHANISM; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME; XEROSTOMIA; CANCER STAGING; CLINICAL TRIAL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904100512     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.006     Document Type: Article

References (51)

1. Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30(May (13)):1541-1549.
2. Goldberg M., Imbernon E., Rolland P., Gild Soit llg A., Savès M., de Quillacq A., et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006, 63(June (6)):390-395.
3. Bianchi C., Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007, 45(June (3)):379-387.
4. Opitz I., Weder W. Malignant pleural mesothelioma. Ther Umsch 2012, 69(July (7)):401-405.
5. Ploenes T., Osel-Agyemang T., Nestle, U., Waller C.F., Passlick B. Malignant pleural mesothelioma. Dtsch Med Wochenschr 2012, 137(March (10)):481-486.
6. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant pleural mesothelioma. J Clin Oncol 2009, 27(April (12)):2081-2090.
7. Treasure T., Lang-Lazdunski L., Waller D., Bliss J.M., Tan C., Entwisle J., et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011, 12(August (8)):763-772.
8. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(July (14)):2636-2644.
9. Van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889.
10. Grosso F., Scagliotti G.V. Systemic treatment of malignant pleural mesothelioma. Future Oncol 2012, 8(March (3)):293-305.
11. Ceresoli G.L., Zucali P.A., Gianoncelli L., Lorenzi E., Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010, 36(February (1)):24-32.
12. Zauderer M.G., Kass S.L., Woo K., Sima C.S., Ginsberg M.S., Krug L.M. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014, (March 14). [Epub ahead of print].
13. Astoul P., Roca E., Galateau-Salle F., Scherpereel A. Malignant pleural mesothelioma: from the bench to the bedside. Respiration 2012, 83(6):481-493.
14. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC cancer staging manual 2010, Springer, New York. 7th edition.
15. Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleuralmesothelioma. Lung Cancer 2009, 63(1):94-97.
16. Zucali P.A., Perrino M., Lorenzi E., Ceresoli G.L., De Vincenzo F., Simonelli M., et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2013, [Epub ahead of print].
17. Van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A phase II study of gemcitabine in patients with malignantpleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999, 85(12):2577-2582.
18. Kindler H.L., Millard F., Herndon J.E., Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31(2-3):311-317.
19. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
20. Zucali P.A., Simonelli M., Michetti G., Tiseo M., Ceresoli G.L., Collovà E., et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012, 75(March (3)):360-367.
21. Ceresoli G.L., Zucali P.A., De Vincenzo F., Gianoncelli L., Simonelli M., Lorenzi E., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72(April (1)):73-77.
22. Filiberti R., Marroni P., Neri M., Ardizzoni A., Betta P.G., Cafferata M.A., et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005, 26(5):221-226.
23. Arber D.A., Tamayo R., Weiss L.M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998, 29(5):498-504.
24. Jakobsen J.N., Sorensen J.B. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 2011, 68:1-15.
25. Destro A., Ceresoli G., Falleni M., Zucali P.A., Morenghi E., Bianchi P., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 2006, 51:207-215.
26. Mathy A., Baas P., Dalesio O., van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005, 50:83.
27. Porta C., Mutti L., Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007, 59:149.
28. Govindan R., Kratzke R.A., Herndon J.E., Niehans G.A., Vollmer R., Watson D., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300.
29. Garland L.L., Rankin C., Gandara D.R., Rivkin S.E., Scott K.M., Nagle R.B., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406.
30. Dowell J., Kindler H. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 2005, 19:1137-1145.
31. Jahan T.M., Gu L., Wang X., Kratzke R.A., Dudek A.Z., Green M.R., et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol 2006, 24(18):70-81.
32. Jänne P.A., Wang X.F., Krug L.M., Hodgson L., Vokes E.E., Kindler H.L. Sorafenib in malignant mesothelioma: a phase II trial of the Cancer and Leukemia Group B (CALGB 30307) (abstract). Proc Am Soc Clin Oncol 2007, 25(18S):7707.
33. Nowak A.K., Millward M.J., Francis R., van der Schaaf A., Musk A.W., Byrne M.J. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) (abstract). Proc Am Soc Clin Oncol 2008, 26:63-80.
34. Buikhuisen W.A., Burgers J.A., Vincent A.D., Korse C.M., van Klaveren R.J., Schramel F.M., et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 2013, 14(May (6)):543-551.
35. Kindler H.L., Karrison T.G., Gandara D.R., Lu C., Krug L.M., Stevenson J.P., et al. Multi-center, double blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30(July (20)):2509-2515.
36. Ceresoli G.L., Zucali P.A., Mencoboni M., Botta M., Grossi F., Cortinovis D., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013, 109(August (3)):552-558.
37. Zalcman G., Margery J., Scherpereel A., Astoul P., Monnet I., Milleron B.J., et al. IFCT-GFPC-0701 MAPS trial, a multicentre randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 2010, 28:15. [abstract].
38. Tsao A.T., He D., Saigal B., Liu S., Lee J.J., Bakkannagari S., et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007, 6(7):1962-1972.
39. Krug L.M., Curley T., Schwartz L., Richardson S., Marks P., Chiao J., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7(4):257-261.
40. Sartore-Bianchi A., Gasparri F., Galvani A., Nici L., Darnowski J.W., Barbone D., et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13:5942-5951.
41. Gordon G.J., Mani M., Maulik G., Mukhopadhyay L., Yeap B.Y., Kindler H.L., et al. Preclinical studies of the proteasome inhibitor Bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008, 61(4):549-558.
42. Josine M., Quispel-Janssen J., Baas P. Emerging therapies for malignant pleural mesothelioma. Curr Respir Care Rep 2012, 1:91-100.
43. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
44. Krug L.M., Kindler H., Calvert H., Manegold C., Tsao A.S., Fennell D., et al. VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 2011, 47(September (Supplement 2)):2-3.
45. Ferté C., Fernandez M., Hollebecque A., Koscielny S., Levy A., Massard C., et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014, 20(January (1)):246-252.
46. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(October (10)):1011-1019.
47. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(July (2)):123-134.
48. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(September (12)):1164-1172.
49. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(February (2)):257-260.
50. Stahel R.A., Weder W., Lievens Y., Felip E. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(May (Suppl. 5)):v126-v128.
51. Ferte C., Massard C., Ileana E., Hollebecque A., Lacroix L., Ammari S., et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Abstract CT 240. AACR annual meeting 2014.